High interdigestive and postprandial motilin levels in patients with the irritable bowel syndrome

Simrén, Magnus; Bjõrnsson, Einar; Abrahamsson, Hasse

doi:10.1111/j.1365-2982.2004.00582.x

Cited by 29 publications

(15 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The secretion of motilin is regulated by neuropsychic factors and affected by eating [37-40]. Zhang et al [39] Measured plasma motilin of 21 patients with STC and 33 heathly people in fasting and one hour postprandial, and found that fasting motilin of STC patients was lower than those healthy people, but the difference was not significant (p > 0.05), which is inconsistent with our study.…”

Section: Discussioncontrasting

confidence: 99%

Clinical Research on the Relation Between Body Mass Index, Motilin and Slow Transit Constipation

et al. 2010

View full text Add to dashboard Cite

BackgroundConstipation is a common clinical symptom but its etiology remains unknown. The aims of the study are to discuss the relation between body mass index (BMI), motilin and the slow transit constipation (STC).MethodsA total of 178 patients with STC and 123 healthy volunteers as controls were divided into three groups according to the BMI, group A (BMI <20), group B (BMI 20-25), and group C (BMI > 25). Fasting and one hour postprandial plasma motilin were measured and the results were analyzed.ResultsThere was significant difference in the constituent ratio between STC patients and healthy controls (p < 0.05). The percentage of group A, B and C in STC patients was 49.4% (88/178), 23.0% (41/178) and 27.6% (49/178), respectively; and group A had a higher percentage. Plasma motilin of fasting and one hour postprandial in STC patients of group A was significantly lower than that of group B and C (p < 0.05), but there was no difference between group B and C (p > 0.05). There was no significant difference in the results of plasma motilin of fasting and one hour postprandial among the three groups of healthy controls (p > 0.05). Plasma motilin of fasting and one hour postprandial in STC patients of group A was significantly lower than those healthy controls of group A (p < 0.05). The same results of plasma motilin of fasting and one hour postprandial could be seen in group B and C, respectively (p < 0.05).ConclusionsA higher proportion of low BMI sufferers was found in the STC patients. The reason may be related to the lower release of the plasma motilin.

show abstract

Section: Discussioncontrasting

confidence: 99%

Clinical Research on the Relation Between Body Mass Index, Motilin and Slow Transit Constipation

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Serotonin and motilin have been altered in IBS patients. A study showed enhanced motilin in diarrhea-predominant patients,70 while another study showed increased motilin in diarrhea-predominant and constipation-predominant patients 71. Despite finding no difference of plasma ghrelin concentration, Sjolund et al29 reported that the ratio of acyl-ghrelin to total ghrelin decreases.…”

Section: Ghrelin In Functional Gi Disordersmentioning

confidence: 98%

Role of Ghrelin in the Pathophysiology of Gastrointestinal Disease

Cheung

2013

Gut Liver

View full text Add to dashboard Cite

Ghrelin is a 28-amino-acid peptide that plays multiple roles in humans and other mammals. The functions of ghrelin include food intake regulation, gastrointestinal (GI) motility, and acid secretion by the GI tract. Many GI disorders involving infection, inflammation, and malignancy are also correlated with altered ghrelin production and secretion. Although suppressed ghrelin responses have already been observed in various GI disorders, such as chronic gastritis, Helicobacter pylori infection, irritable bowel syndrome, functional dyspepsia, and cachexia, elevated ghrelin responses have also been reported in celiac disease and inflammatory bowel disease. Moreover, we recently reported that decreased fasting and postprandial ghrelin levels were observed in female patients with functional dyspepsia compared with healthy subjects. These alterations of ghrelin responses were significantly correlated with meal-related symptoms (bloating and early satiation) in female functional dyspepsia patients. We therefore support the notion that abnormal ghrelin responses may play important roles in various GI disorders. Furthermore, human clinical trials and animal studies involving the administration of ghrelin or its receptor agonists have shown promising improvements in gastroparesis, anorexia, and cancer. This review summarizes the impact of ghrelin, its family of peptides, and its receptors on GI diseases and proposes ghrelin modulation as a potential therapy.

show abstract

“…Increased blood levels of motilin have been associated with lower bowel disorders rather than upper gut disorders. For example, increased blood levels of motilin have been reported in patients with diarrhoea-or constipation-predominant forms of irritable bowel syndrome (IBS; Simrén et al, 2005). In addition, increased release of motilin has been reported in IBS patients undergoing psychological stress (in which colonic motility was also increased; Fukudo and Suzuki, 1987) and in constipation-predominant IBS patients receiving an infusion of intraduodenal lipids (there was a tendency for motilin concentrations to be reduced in the diarrhoea-predominant group; Simrén et al, 2001).…”

Section: Functions Of Endogenous Motilinmentioning

confidence: 99%

Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists

Sanger

Wang

Hobson

et al. 2013

British J Pharmacology

View full text Add to dashboard Cite

The gastrointestinal hormone motilin has been known about for >40 years, but after identification of its receptor and subsequent development of new tools and methods, a reappraisal of its actions is required. Firstly, it is important to note that motilin and ghrelin receptors are members of the same family (similar genomic organization, gastrointestinal distribution and abilities to stimulate gastrointestinal motility), yet each fails to recognize the ligand of the other; and whereas ghrelin and ghrelin receptors are widespread outside the gastrointestinal tract, motilin and its receptors are largely restricted to the gastrointestinal tract. Secondly, although some studies suggest motilin has activity in rodents, most do not, and receptor pseudogenes exist in rodents. Thirdly, motilin preferentially operates by facilitating enteric cholinergic activity rather than directly contracting the muscle, despite the relatively high expression of receptor immunoreactivity in muscle. This activity is ligand-dependent, with short-lasting actions of motilin contrasting with longer-lasting actions of the non-selective and selective motilin receptor agonists erythromycin and GSK962040. Finally, the use of erythromycin (also an antibiotic drug) to treat patients requiring acceleration of gastric emptying has led to concerns over safety and potential exacerbation of antibiotic resistance. Replacement motilin receptor agonists derived from erythromycin (motilides) have been unsuccessful. New, non-motilide, small molecule receptor agonists, designed to minimize self-desensitization, are now entering clinical trials for treating patients undergoing enteral feeding or with diabetic gastroparesis. Thus, for the translational pharmacologist, the study of motilin illustrates the need to avoid overreliance on artificial systems, on structural information and on animal studies. LINKED ARTICLESThis article is part of a themed section on Neuropeptides. To view the other articles in this section visit http://dx

show abstract

High interdigestive and postprandial motilin levels in patients with the irritable bowel syndrome

Cited by 29 publications

References 45 publications

Clinical Research on the Relation Between Body Mass Index, Motilin and Slow Transit Constipation

Clinical Research on the Relation Between Body Mass Index, Motilin and Slow Transit Constipation

Role of Ghrelin in the Pathophysiology of Gastrointestinal Disease

Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists

Contact Info

Product

Resources

About